12:00 AM
 | 
Aug 10, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afinitor everolimus regulatory update

The EC approved an MAA from Novartis for Afinitor everolimus to treat advanced renal cell carcinoma (RCC) in patients whose disease progressed on or after treatment with VEGF-targeted therapy. The oral...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >